NPPB and COVID-19: In the present prospective study, COVID-19 survivors were evaluated after a relatively long time period with a median interval of 327 days after diagnosis, and no elevation of cTnI and NT-proBNP were detected nor echocardiographic structural and functional abnormalities were found when compared with healthy control and risk factor-matched control, including those with myocardial injury in the acute phase.